ALX Oncology appoints Scott Garland to Board of Directors effective Nov 28, 2022

ALX ONCOLOGY HOLDINGS INC

Appointed Scott Garland to Board of Directors effective November 28, 2022; Board size increased from 7 to 8.
Garland is CEO of PACT Pharma, former CEO of Portola Pharmaceuticals, with 30+ years in biopharma.
Automatic grant of initial stock options for 24,009 shares, vesting monthly over three years.
Garland also serves on boards of Calithera Biosciences and Day One Biopharmaceuticals.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Garland

Director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2022-11-28
Filed: November 29, 2022, 6:59 PM ET

Effective as of November 28, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Scott Garland to its Board of Directors and increased the size of its Board of Directors from seven to eight directors in connection with his appointment.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Garland was appointed as Director at ALX ONCOLOGY HOLDINGS INC.

Action: appointed
Role: Director

Exact text from the filing

Effective as of November 28, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Scott Garland to its Board of Directors and increased the size of its Board of Directors from seven to eight directors in connection with his appointment.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-025765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.